Antineoplastic and immunomodulating agents

Filters
Category
Release Form
Primary Package
Status
Dossier Type
Search

Antineoplastic and immunomodulating agents

Cyproterone

Antineoplastic and immunomodulating agents

Tablets Solution for Injection in oil

Tablets

50mg, 100mg

Blister, Rx, CTD
Solution for Injection in oil

100mg/mL: 3mL

Ampoule, Rx, CTD
More Less

Flutamide

Antineoplastic and immunomodulating agents

Tablets

Tablets

125mg, 250mg

Blister, Rx, CTD
More Less

Letrozole

Antineoplastic and immunomodulating agents

Film-coated Tablets

Film-coated Tablets

2.5mg

Blister, Rx, CTD
More Less

Tofacitinib

Antineoplastic and immunomodulating agents

Film-coated Tablets

Film-coated Tablets

5mg, 10mg

Blister, Rx, EU CTD
More Less

Farmak International is an oncology pharmaceuticals supplier. We focus on primary market segments, producing medicines that stimulate or suppress the immune system to inhibit tumour growth and treat other related conditions.

Oncology & Immunomodulation Product Portfolio

Developing our assortment, we combine products intended for targeted therapies. Our CTD-ready portfolio encompasses institutional cancer medications used as hormone therapy for hormone-dependent cancers. The mechanism of their action is based on blocking hormones from fueling cancer cell growth or reducing the production of the body’s hormones. We offer three classes from the category:

  • Antiandrogens for prostate cancer management. Being a prostate cancer medication supplier, we offer Cyproterone and Flutamide. They compete with testosterone and dihydrotestosterone for binding to intracellular androgen receptors and block signals that support cancer cell proliferation.
  • Aromatase inhibitors for breast cancer treatment. Letrozole is one of the most efficient breast cancer treatment pharmaceuticals. It blocks the aromatase enzyme from converting androgens into estrogens, thereby stopping disease progression.
  • Immunomodulatory agents. Typically, JAK inhibitors are used to treat chronic inflammatory and autoimmune diseases. As part of cancer therapy, they enhance immune responses to cancer. As a JAK inhibitor supplier, we offer Tofacitinib. Rather than directly killing cancer cells, the medication treats inflammatory diseases, being an immunosuppressive drug that also reduces pro-growth signaling.

We are not a distributor of cytotoxic agents. Our generic oncology medications mostly block hormone receptors, which prevents the production of natural hormones (like estrogen or testosterone) that hormone-sensitive cancer cells need to grow.

Institutional Supply Applications

As an immunomodulatory agent and generic oncology drug distributor, we deliver our products to pharmaceutical companies, distributors, hospitals, procurement organizations, and healthcare partners. Our oncology formulary products are widely used in hospital oncology departments, cancer treatment centres, antiandrogen supplier hospitals, and other specialised clinics.

We manufacture and supply EU GMP-certified medicines and prepare tender-ready dossiers for submission directly to global pharmacy procurement organisations for formulary inclusion. Also, we take part in tenders and compete for procurement contracts to handle oncology pharmacy supplies to European and global markets.

Product Specifications & Formulations

Our offering features medications with various physical designs. A route of administration impacts bioavailability, absorption speed, usability, and even shelf life. Some formulations of hormone therapy cancer medications are better for emergencies where immediate initiation of effect is crucial. Others are more convenient for a patient to take medication. We offer both tablets and solutions for injections in oil with diverse dosage strengths. Some tabs are film-coated to mask tastes, protect against moisture, and ensure easy swallowing. Medications are packaged in blisters and ampules to be stored according to the regulatory requirements to maintain stability.

Quality Assurance & Regulatory Compliance

As an antineoplastic drugs distributor, we broaden our reach in well-regulated markets by offering high-quality products that meet international standards. Quality is at the core of our business. To confirm this, we hold vital national and international approvals, including EU GMP certification.

Our GMP-certified manufacturing is highly regulated and sterile to ensure that cancer-fighting drugs are consistently produced and properly packaged.

To be a legal antiandrogen, hormone therapy, and aromatase inhibitors distributor, we are legally obligated to forward any adverse event reports, product complaints, or quality defects we receive from our partners directly to the Marketing Authorisation Holder. We perform pharmacovigilance and safety monitoring across the medical product lifecycle.

Partnership for Oncology Product Supply

Thanks to a long-standing international reach as a cancer treatment medication supplier and our brand awareness, Farmak International ensures reliable availability of critical oncology medications. We offer competitive pricing possible due to initially favourable specialised rates and discounts that additionally can be negotiated with large healthcare buyers.

We prepare a comprehensive regulatory dossier that proves product safety, efficacy, and quality, including our GMP certificates and certificate of analysis, and a comprehensive product dossier containing chemistry, manufacturing, and controls (CMC) data. This set of documentation is sufficient to submit for participation in tenders. Also, we provide technical support for hospital pharmacies.

We can boast a market presence in Central and Eastern Europe, Central Asia, and the Middle East and North Africa, particularly in the UAE, where we meet the growing demand for high-quality medications.